Results 21 to 30 of about 197,154 (267)

Immune checkpoint inhibitor myocarditis: a systematic case study

open access: yesРоссийский кардиологический журнал, 2020
Myocarditis is a life-threatening complication of immune checkpoint inhibitor therapy. Over the past ten years, drugs in this group have been used in the treatment of a wide range of hematological diseases and solid tumors.
E. A. Kushnareva, O. M. Moiseeva
doaj   +1 more source

Bronchiolitis Obliterans after Combination Immunotherapy with Pembrolizumab and Ipilimumab [PDF]

open access: yesJournal of Immunotherapy and Precision Oncology, 2018
Checkpoint inhibitor therapies are members of a new, groundbreaking class of drugs that reinvigorate the immune system to directly attack tumors.
Amulya Balagani   +2 more
doaj   +1 more source

Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas

open access: yesiScience, 2023
Summary: Evidence is mounting for cross-resistance between immune checkpoint and targeted kinase inhibitor therapies in cutaneous melanoma patients. Since the loss of the transcription factor, SOX10, causes tolerance to MAPK pathway inhibitors, we used ...
Timothy J. Purwin   +4 more
doaj   +1 more source

Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes mellitus: A report of two cases

open access: yesClinical Case Reports, 2021
Immune checkpoint inhibitor‐induced diabetes mellitus is a rare immune‐related adverse event. This report illustrates clinical data and insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes.
Noriko Fujiwara   +7 more
doaj   +1 more source

Immune checkpoint inhibitors in malignancy [PDF]

open access: yesAustralian Prescriber, 2019
Immune checkpoints normally stop the body from mounting an immune response against healthy cells. Some cancers can acquire these checkpoints so that the tumour cells are not recognised by the immune systemInhibiting the checkpoints therefore enables the tumour cells to be recognised and allows an immune response to be activated against themImmune ...
Luke, Ardolino, Anthony, Joshua
openaire   +2 more sources

Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab

open access: yesAdvances in Cancer Biology - Metastasis, 2022
This case report presents a patient with metastatic malignant melanoma who was treated with immunotherapy with the PD-1 checkpoint inhibitor pembrolizumab and developed a rare neurological immune-related adverse event (irAE) limbic encephalitis.
Rozala Arko, Nina Boc, Marko Boc
doaj   +1 more source

Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation

open access: yesPulmonary Circulation, 2021
Immunologic risk factors contribute to endothelial dysfunction and development of pulmonary vascular disease. Immune checkpoint inhibitors, used as immunotherapies for malignancies, have a wide range of reported immune-related adverse events.
Ruben Mylvaganam   +6 more
doaj   +1 more source

Immune checkpoint inhibitors [PDF]

open access: yesJournal of Cell Biology, 2019
Hui details the cell biology underlying the action of immune checkpoint inhibitors.
openaire   +4 more sources

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?

open access: yesFrontiers in Immunology, 2022
Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has ...
Xinye Qian   +5 more
doaj   +1 more source

Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer

open access: yesScientific Reports, 2023
Immune checkpoint inhibitors have significantly improved the prognosis in patients with non-small cell lung cancer, compared with cytotoxic agents.
Minehiko Inomata   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy